Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel expects that the biopharmaceutical company will post earnings of ($0.92) per share for the quarter. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($0.92) EPS and Q3 2025 earnings at ($0.92) EPS.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.24.
Several other analysts have also issued reports on the company. Wedbush restated an "outperform" rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and set a $50.00 target price (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. William Blair assumed coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Finally, Jefferies Financial Group lowered their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $59.13.
Read Our Latest Research Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Stock Performance
NASDAQ CRBP traded down $0.63 during trading hours on Friday, hitting $6.33. 309,335 shares of the company traded hands, compared to its average volume of 365,581. The business's 50-day moving average is $9.32 and its 200-day moving average is $18.10. The stock has a market capitalization of $77.09 million, a price-to-earnings ratio of -1.35 and a beta of 2.63. Corbus Pharmaceuticals has a twelve month low of $6.26 and a twelve month high of $61.90.
Institutional Trading of Corbus Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 1,172 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Corbus Pharmaceuticals by 7.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company's stock valued at $469,000 after purchasing an additional 1,600 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Corbus Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 2,195 shares during the last quarter. FMR LLC boosted its stake in Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 2,486 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 2,616 shares during the last quarter. 64.64% of the stock is owned by institutional investors.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Featured Articles
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
